JMP Securities began coverage on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a report released on Monday. The brokerage set an “outperform” rating and a $23.00 price target on the stock. JMP Securities’ target price indicates a potential upside of 108.52% from the company’s previous close.

A number of other equities analysts have also recently commented on MYOV. Barclays PLC assumed coverage on shares of Myovant Sciences in a research note on Monday. They issued an “overweight” rating and a $18.00 price objective for the company. Robert W. Baird assumed coverage on shares of Myovant Sciences in a research note on Monday. They issued an “outperform” rating and a $20.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Myovant Sciences presently has a consensus rating of “Buy” and a consensus target price of $20.33.

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Myovant Sciences (NASDAQ:MYOV) opened at 11.03 on Monday. The company’s market cap is $480.80 million. The stock has a 50 day moving average of $11.40 and a 200 day moving average of $11.40. Myovant Sciences has a 12-month low of $10.26 and a 12-month high of $13.31.

TRADEMARK VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and reposted in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2016/11/23/myovant-sciences-ltd-myov-now-covered-by-jmp-securities.html.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

5 Day Chart for NASDAQ:MYOV

Receive News & Stock Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related stocks with our FREE daily email newsletter.